Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related mortality worldwide. For patients with embolization-eligible unresectable HCC, TACE has long been considered the global standard of care. However, recurrence and disease progression remain common, highlighting the need for more effective treatment approaches.

The single tremelimumab regular interval durvalumab (STRIDE) regimen already demonstrated durable overall survival benefits in advanced HCC and is established as a standard-of-care immunotherapy option. The Phase III EMERALD-3 trial explored whether integrating STRIDE, with or without lenvatinib, alongside TACE could further improve outcomes in patients with earlier-stage unresectable disease.

The study evaluated STRIDE plus lenvatinib and TACE (STRIDE + L + TACE), STRIDE plus TACE, and TACE alone, with progression-free survival (PFS) as the primary endpoint.

Safety Outcomes-

• Grade 3/4 treatment-related adverse events occurred in:

• 62.7% of patients receiving STRIDE + L + TACE

• 48.6% of patients receiving STRIDE + TACE

• 18.6% of patients receiving TACE alone

• No unexpected safety findings or new safety signals were reported.

KOL Insights-

“EMERALD-3 further demonstrates that introducing the dual immunotherapy STRIDE regimen earlier, in combination with TACE and lenvatinib, may improve outcomes in patients with earlier-stage liver cancer. These findings build on results from the HIMALAYA phase 3 trial in advanced, unresectable disease, where the STRIDE regimen previously demonstrated durable overall survival (OS) benefit.”– Expert Opinion

“Dual immunotherapy with durvalumab and tremelimumab in the STRIDE (single tremelimumab regular interval durvalumab) regimen represents a meaningful advance for patients with embolization-eligible liver cancer, who currently have limited systemic treatment options to prevent disease progression or recurrence. The regimen has also shown a trend toward improved survival outcomes.”– Expert Opinion

Conclusion-

Globally, more than 800,000 people are diagnosed with liver cancer each year. Hepatocellular carcinoma is more common in men than women. Recently HCC cases are declining; this decline may be partly associated with national hepatitis screening and treatment initiatives and professional guidelines, emphasizing continued efforts to address both viral and non-viral causes.

The results reflect a rapidly evolving HCC treatment paradigm and provide important evidence regarding treatment utilization in the initial era of novel systemic therapies. In addition, favorable overall survival trends were observed for both STRIDE-containing regimens, with STRIDE plus TACE showing improvements in both PFS and OS compared with TACE alone.